Clinical Trial Update: Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating cabozantinib in RET fusion-positive advanced non-small cell lung cancer and in patients with ROS1, NTRK fusions, or increas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: RECRUITING